The University of Chicago Header Logo

Connection

Stuart Sprague to Parathyroid Hormone

Back to Details
This is a "connection" page, showing publications Stuart Sprague has written about Parathyroid Hormone.
Stuart Sprague
Connection Strength
4.682
Parathyroid Hormone
  1. Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol. 2013 Feb; 8(2):321.
    View in: PubMed
    Score: 0.344
  2. The case for routine parathyroid hormone monitoring. Clin J Am Soc Nephrol. 2013 Feb; 8(2):313-8.
    View in: PubMed
    Score: 0.341
  3. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol. 2009 Sep; 4(9):1465-76.
    View in: PubMed
    Score: 0.275
  4. When is Vitamin D contraindicated in dialysis patients? Semin Dial. 2009 May-Jun; 22(3):249-51.
    View in: PubMed
    Score: 0.269
  5. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27(1):36-43.
    View in: PubMed
    Score: 0.229
  6. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.
    View in: PubMed
    Score: 0.205
  7. Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of Transitional Drug Add-On Payment Adjustment Designation. Clin J Am Soc Nephrol. 2025 Feb 01; 20(2):218-228.
    View in: PubMed
    Score: 0.196
  8. Sustained Reduction of Elevated Intact Parathyroid Hormone Concentrations with Extended-Release Calcifediol Slows Chronic Kidney Disease Progression in Secondary Hyperparathyroidism Patients. Am J Nephrol. 2026; 57(4):504-513.
    View in: PubMed
    Score: 0.194
  9. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024 06; 41(6):2500-2518.
    View in: PubMed
    Score: 0.190
  10. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis. 2001 Nov; 38(5 Suppl 5):S51-6.
    View in: PubMed
    Score: 0.160
  11. Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020 07 01; 15(7):1041-1043.
    View in: PubMed
    Score: 0.145
  12. Parathyroid hormone-induced calcium efflux from cultured bone is mediated by protein kinase C translocation. Am J Physiol. 1996 Dec; 271(6 Pt 2):F1139-46.
    View in: PubMed
    Score: 0.114
  13. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement - A view from the IFCC Working Group for PTH. Clin Chim Acta. 2017 Apr; 467:42-47.
    View in: PubMed
    Score: 0.113
  14. Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
    View in: PubMed
    Score: 0.112
  15. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients. Am J Nephrol. 2016; 44(2):104-12.
    View in: PubMed
    Score: 0.111
  16. We Do Too Many Parathyroidectomies for Calciphylaxis. Semin Dial. 2016 07; 29(4):312-4.
    View in: PubMed
    Score: 0.109
  17. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016 Apr; 67(4):559-66.
    View in: PubMed
    Score: 0.104
  18. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1021-30.
    View in: PubMed
    Score: 0.102
  19. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
    View in: PubMed
    Score: 0.100
  20. Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease. Nephrol Dial Transplant. 2011 Nov; 26(11):3440-5.
    View in: PubMed
    Score: 0.080
  21. Renal bone disease. Curr Opin Endocrinol Diabetes Obes. 2010 Dec; 17(6):535-9.
    View in: PubMed
    Score: 0.075
  22. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant Proc. 2010 Sep; 42(7):2503-8.
    View in: PubMed
    Score: 0.074
  23. Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010 Jul; 20(4):243-54.
    View in: PubMed
    Score: 0.071
  24. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar; 5(3):512-8.
    View in: PubMed
    Score: 0.071
  25. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol. 2009 Oct; 72(4):252-8.
    View in: PubMed
    Score: 0.069
  26. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009 Jan; 4(1):178-85.
    View in: PubMed
    Score: 0.065
  27. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S170-4.
    View in: PubMed
    Score: 0.065
  28. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol. 2008; 28(1):97-106.
    View in: PubMed
    Score: 0.060
  29. Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial. J Bone Miner Res. 2026 Aug 21; 41(9):922-933.
    View in: PubMed
    Score: 0.056
  30. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.
    View in: PubMed
    Score: 0.050
  31. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004 May; 43(5):877-90.
    View in: PubMed
    Score: 0.048
  32. Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90.
    View in: PubMed
    Score: 0.046
  33. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 Apr; 63(4):1483-90.
    View in: PubMed
    Score: 0.044
  34. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003 Jan; 63(1):248-54.
    View in: PubMed
    Score: 0.043
  35. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. Clin Nephrol. 2002 Aug; 58(2):155-60.
    View in: PubMed
    Score: 0.042
  36. Percutaneous bone biopsy in the diagnosis of renal osteodystrophy. Semin Nephrol. 2002 May; 22(3):268-75.
    View in: PubMed
    Score: 0.041
  37. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
    View in: PubMed
    Score: 0.036
  38. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000 May; 15(5):927-35.
    View in: PubMed
    Score: 0.036
  39. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
    View in: PubMed
    Score: 0.034
  40. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
    View in: PubMed
    Score: 0.033
  41. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol. 2015 Jun 05; 10(6):1031-40.
    View in: PubMed
    Score: 0.025
  42. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol. 2016 Feb; 29(1):63-70.
    View in: PubMed
    Score: 0.025
  43. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis. 1992 Jun; 19(6):532-9.
    View in: PubMed
    Score: 0.021
  44. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed? Semin Dial. 2007 Jan-Feb; 20(1):24-32.
    View in: PubMed
    Score: 0.014
  45. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005 Oct; 20(10):2186-93.
    View in: PubMed
    Score: 0.013
  46. Behavioral changes in rats after chronic aluminum and parathyroid hormone administration. Neurobehav Toxicol Teratol. 1982 May-Jun; 4(3):403-10.
    View in: PubMed
    Score: 0.010
  47. Parathyroid hormone-mediated aluminum deposition and egress in the rat. Kidney Int. 1980 Jan; 17(1):40-4.
    View in: PubMed
    Score: 0.009
  48. Effect of prenatal administration of aluminum and parathyroid hormone on fetal development in the rat. Proc Soc Exp Biol Med. 1979 May; 161(1):74-7.
    View in: PubMed
    Score: 0.008
  49. Determinants of tissue aluminum concentration. Am J Kidney Dis. 1981 Nov; 1(3):141-5.
    View in: PubMed
    Score: 0.002
  50. Factors affecting tissue aluminum concentration. J Dial. 1978; 2(5-6):471-81.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.